Recent developments to share with you

Congratulations! Our Company Honored as "Excellent Enterprise" in the 2018 National Entrepreneurship Competition

2022-09-12


Technology innovation drives great achievements. The biomedical industry finals of the 7th China Innovation & Entrepreneurship Competition concluded in Guangzhou on November 15, 2018. A total of 241 outstanding enterprises from across the country stood out from more than 3,500 biomedical companies through preliminary, semi-final, and final rounds at the local level, advancing to the national finals in Guangzhou. Competing projects covered multiple sub-fields, including innovative medical devices, precision medicine, genetic testing, and new drug R&D. After intense competition, 101 excellent enterprises were selected, along with first, second, and third prize winners.

From registration in May, preparation in June, and then advancing through municipal, provincial, and national competitions, the entire process took over six months. It is fair to say that all enterprises that reached the national finals possessed strong capabilities. It is worth celebrating that our company, a research-based technology enterprise just five years old at the time, achieved excellent results in the group finals and earned the title of "Excellent Enterprise."

Sowing Effort, Harvesting Growth! Looking back at our development since our founding in November 2013, the company has continued to expand. Our current R&D laboratory covers nearly 1,600 square meters, with an R&D team of about 30 people and over 20 projects ongoing. The total value of technology transfer agreements has reached approximately RMB 50 million. In 2018, the company was recognized as a Technology-oriented SME, a High-tech Cultivation Enterprise by both Jiangsu Province and Nanjing City and received multiple invention patents.

Five years is both a snapshot of our journey and a look toward the future. As we celebrate the 5th anniversary of our founding, let us warmly congratulate our company on being named an "Excellent Enterprise" in the 2018 National Entrepreneurship Competition, and look forward to the next five glorious years of Kangchuanji's development!

Keywords:

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03